GoodRx Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $796.9M | $792.3M | $750.3M | $766.6M | $745.4M |
| Research and development | $121.0M | $123.7M | $135.8M | $143.1M | $125.9M |
| Operating income | $87.5M | $65.8M | -$27.0M | $1.7M | $13.4M |
| Interest expense | $42.6M | $52.9M | $56.7M | $34.2M | — |
| Pretax income | $56.5M | $31.5M | -$55.6M | -$23.2M | -$10.2M |
| Income tax expense | $26.1M | $15.1M | -$46.7M | $9.6M | $15.1M |
| Net income | $30.4M | $16.4M | -$8.9M | -$32.8M | -$25.3M |
| Balance Sheet | |||||
| Cash and equivalents | $261.8M | $448.3M | $672.3M | $757.2M | $941.1M |
| Current assets | $643.1M | $659.3M | $872.8M | $919.7M | $1.1B |
| Total assets | $1.4B | $1.4B | $1.6B | $1.6B | $1.6B |
| Current liabilities | $246.0M | $123.9M | $122.6M | $76.3M | $81.1M |
| Total liabilities | $787.8M | $663.4M | $826.8M | $789.8M | $775.9M |
| Stockholders' equity | $616.3M | $724.7M | $762.0M | $814.8M | $831.7M |
| Cash Flow Statement | |||||
| Cash from operations | $167.9M | $183.9M | $138.3M | $146.8M | $178.8M |
| Depreciation and amortization | $4.2M | $4.5M | $4.8M | $4.6M | $4.0M |
| Stock-based compensation | $76.6M | $99.0M | $104.8M | $120.2M | $160.5M |
| Capital expenditure | $3.5M | $1.2M | $1.0M | $4.0M | $4.6M |
| Free cash flow | $164.4M | $182.7M | $137.2M | $142.8M | $174.2M |
| Share repurchases | $216.4M | $158.8M | $104.0M | $101.7M | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 338.7M · Free float 8.5%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.